Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirtazapine vs Megestrol Acetate for Cancer Anorexia-Cachexia
NCT05380479Phase 2Unknown
- Sponsor
- Bangabandhu Sheikh Mujib Medical University
- Start
- Jun 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mirtazapine in cancer anorexia-cachexia syndrome (CACS) (2 arms), sponsored by Bangabandhu Sheikh Mujib Medical University. Primary endpoint: Functional Assessment of Anorexia/Cachexia Therapy Score at 8 weeks. Status: unknown.
02
Drugs
mirtazapine
03
Conditions
cancer anorexia-cachexia syndrome (CACS)
Beyond the preview
Go deeper on NCT05380479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05380479.